Trials / Completed
CompletedNCT04478708
Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 133 in Subjects With Obesity
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to assess the safety and tolerability of maridebart cafraglutide as single and multiple doses in participants with obesity
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | maridebart cafraglutide | Participants will receive maridebart cafraglutide as a single dose in Part A and multiple doses in Part B and C. |
| DRUG | Placebo | Participants will receive placebo as a single dose in Part A and multiple doses in Part B. |
Timeline
- Start date
- 2020-08-07
- Primary completion
- 2022-11-18
- Completion
- 2022-11-18
- First posted
- 2020-07-21
- Last updated
- 2025-12-10
- Results posted
- 2025-12-10
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04478708. Inclusion in this directory is not an endorsement.